Last checked at 10 Jun 2013 13:39
For immediate release | 10 June 2013 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
CULS Conversion and Additional Listing
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has received a conversion request in respect of £102,000 nominal value of the Company's 8% Convertible Unsecured Loan Stock. Accordingly, the Company has allotted 485,713 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to admission of the Ordinary Shares to trading on AIM.
Application has been made by Alliance for the 485,713 Ordinary Shares to be admitted to trading on AIM, and it is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 14th June 2013.
Following conversion and allotment, Alliance will have 249,055,267 Ordinary Shares and £2,952,025 of 8% Convertible Unsecured Loan Stock in issue.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 | |
John Dawson, Chief Executive | ||
Richard Wright, Finance Director | ||
| ||
Buchanan | + 44 (0) 20 7466 5000 | |
Mark Court / Fiona Henson / Sophie Cowles | ||
Numis Securities Limited | + 44 (0) 20 7260 1000 | |
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield | ||
Corporate Broking: David Poutney | ||
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.